HPV Testing And Pap Test - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the HPV testing and pap test market size is expected to grow from USD 6.89 billion in 2025 to USD 7.59 billion in 2026 and is forecast to reach USD 12.58 billion by 2031 at 10.63% CAGR over 2026-2031.

This report is Segmented by Test Type (HPV Test, Pap Test, Co-Test), Product Type (Instruments and Analyzers, and More), Technology (PCR/NAAT, and More), Application (Cervical Cancer Screening, and More), End User (Hospitals & Clinics, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). Market Forecasts are Provided in Terms of Value (USD).

Global HPV Testing And Pap Test Market Trends and Insights

Rising Prevalence of HPV Infections and Cervical Cancer Burden

Global cervical cancer incidence climbed 4.2% between 2020 and 2024, reversing earlier gains tied to Pap campaigns. Screening gaps created during the pandemic left an estimated 35 million women untested, allowing lesions to progress unchecked. South Asia and Sub-Saharan Africa now carry 70% of mortality, pushing ministries to subsidize molecular HPV tests that deliver 90-95% sensitivity. Shifts in the genotype mix of non-vaccine types 31, 33, 45, 52, and 58 are now more common among women aged 30-39, spurring laboratories to adopt extended-genotyping assays that guide risk-stratified management. Regulators responded in 2024 by publishing draft guidance that formalizes genotyping reflex pathways, streamlines triage, and enhances test value.

Expanding Government-Funded Screening Programs and New Guidelines Favoring HPV Primary Testing

The 2024 USPSTF Grade A recommendation for HPV primary testing catalyzed immediate payer alignment, with major U.S. insurers raising reimbursement to USD 65-72 per assay. England finalized its nationwide switch to HPV-first screening, cutting cytology workload 40% and halving turnaround times. China earmarked RMB 12 billion (USD 1.65 billion) to screen 120 million rural women using domestic PCR kits, while India incorporated HPV testing into its Ayushman Bharat scheme, achieving 62% uptake in pilot states. These mandates compress replacement cycles for legacy microscopes, driving orders for automated molecular platforms and fueling the HPV testing and pap test market in the near term.

High Cost of Advanced Molecular Tests in Low-Resource Settings

PCR-based HPV tests cost USD 15-25 per sample in low- and middle-income countries, compared to USD 2-5 for visual inspection with acetic acid (VIA), the dominant screening method in Sub-Saharan Africa where per-capita health spending averages USD 50 annually. This price gap restricts molecular test adoption to urban tertiary hospitals and donor-funded pilot programs, leaving 80% of the at-risk population reliant on VIA, which has 50-60% sensitivity for high-grade lesions, compared with 90-95% for HPV DNA tests. Zambia's Ministry of Health piloted Cepheid's GeneXpert HPV assay in 2024 across 15 rural clinics, achieving 68% screening uptake, but suspended expansion after donor funding lapsed, citing unsustainable reagent costs of USD 18 per test. India's public health system negotiated HPV test prices down to USD 5-6 through bulk procurement, yet state budgets cover only 40% of eligible women, forcing rationing that prioritizes high-risk age groups (35-45) and excludes younger cohorts.

Other drivers and restraints analyzed in the detailed report include:

1. Technological Advancements in Molecular Diagnostics
2. AI-Enabled Cytology & Digital Pathology Alleviating Pathologist Shortages
3. Rising HPV Vaccination Coverage Reducing Long-Term Screening Volumes

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

HPV Tests are advancing at a 11.26% CAGR, eating into Pap Tests' 53.02% share of the HPV testing and Pap test market recorded in 2025. The USPSTF guidance that elevates HPV primary screening triggered immediate coverage shifts, making standalone molecular assays the economical choice for laboratories processing 300-500 samples per shift.

Self-collection kits cleared in 2024 further accelerate adoption among women overdue for exams, boosting screening uptake by 28% in a large U.S. randomized study. Co-testing persists where malpractice concerns linger, though its 20% volume share is sliding as payers curtail dual-test reimbursement. In emerging markets, Pap Tests remain relevant for facilities lacking PCR capacity, yet falling instrument prices and reagent localization are steadily broadening access to HPV tests, expanding the HPV testing and Pap test market size at double-digit rates.

Recurring reagent sales delivered 54.17% of revenue in 2025, but software platforms are on course for a 12.35% CAGR as AI engines and cloud dashboards move cervical screening into integrated women's health portals. Hologic's Genius platform alone generated USD 180 million in license and subscription revenue in 2025, proof that digital layers now rival consumables in value capture.

Hospitals facing budget freezes increasingly favor software-as-a-service contracts over capital purchases, a pivot that locks clients into multi-year agreements and stabilizes vendor cash flows. Meanwhile, instruments and analyzers lengthen refresh cycles to 8-10 years, dampening hardware demand but broadening installed bases for future software attach. Services training, validation, and maintenance account for 10% of turnover and offer cross-sell opportunities for vendors seeking a holistic share of wallet in the HPV testing and pap test market.

Complete Report Scope:

• By Test Type
  • HPV Test
  • Pap Test
  • Co-test (HPV + Pap)
• By Product Type
  • Instruments and Analyzers
  • Consumables and Reagents
  • Software Platforms
  • Services
• By Technology
  • PCR / NAAT
  • Hybrid Capture
  • mRNA-based Assays
  • Next-Generation Sequencing
• By Application
  • Cervical Cancer Screening
  • Vaginal Cancer Screening
  • Post-treatment Follow-up
  • Clinical Trials & Epidemiology
• By End User
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 43.78% of the HPV testing and Pap test market revenue in 2025. The USPSTF Grade A rating for HPV primary testing spurred reimbursement increases, yet vaccination progress and five-year screening intervals constrain absolute volume growth. Canada's shift to HPV testing in its three largest provinces demonstrates provincial momentum, even as smaller regions weigh budget impacts. Mexico's Seguro Popular program introduced HPV assays in 2024, but uneven lab capacity outside major metros slows uptake.

Asia-Pacific is expanding the fastest, with a 14.97% CAGR. China's RMB 12 billion initiative to screen 120 million women using local PCR kits anchors volume, while India's Ayushman Bharat integration lifted participation to 62% in pilot states. Japan resumed pro-vaccine policy in 2024 and lengthened intervals for vaccinated women, tempering near-term test counts but firming long-range demand through broader prevention. South Korea's 2025 age-band expansion adds 4 million annual tests, even though reimbursement trails true cost.

England finalized its HPV-first rollout, Germany mandated tri-annual HPV screening for women >=35, and France approved HPV primary testing though regional systems staggered implementation. Middle East & Africa and South America combined for 8% share; limited budgets and reagent stockouts inhibit scale, though donor-backed pilots in Brazil, South Africa, and Zambia validate demand when funding aligns. Overall, geographic variance hinges on policy maturity, payer generosity, and laboratory infrastructure, but Asia-Pacific's momentum offsets plateauing North America, keeping the global HPV testing and pap test market on a solid growth arc.

1. Abbott Laboratories
2. Arbor Vita
3. Beckton Dickinson
4. bioMerieux
5. Cepheid (Danaher)
6. Femasys Inc.
7. Fujirebio Diagnostics
8. Guangdong Hybribio Biotech
9. Guided Therapeutics
10. Hologic
11. Illumina
12. LabCorp
13. OncoHealth Corp.
14. QIAGEN
15. Quest Diagnostics
16. Roche
17. Sansure Biotech
18. Seegene
19. Siemens Healthineers
20. Thermo Fisher Scientific
21. Triplex International Biosciences
22. Zytovision GmbH

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support